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This debate focuses on whether, and to what extent, loss of small precapillary arteries is associated with the
elevation in pulmonary artery pressure and resistance that accompanies chronic hypoxia-induced pulmonary
hypertension. The issue has become the focus of much debate for a number of reasons. Papers from McLoughlin
and his group (5, 6) have provided conclusive evidence that there is considerable angiogenesis associated with

hypoxia-induced pulmonary hypertension. In addition, Rho kinase inhibitors normalize pulmonary pressure in
chronic hypoxia presumably by a pure vasodilatory action (7).
The fact that chronic hypoxia can stimulate neoangiogenesis does not negate the fact that chronic hypoxia can
also result in loss of precapillary arteries. It is now generally accepted that loss of distal arteries in the clinical
and experimental setting of pulmonary hypertension is the result of apoptosis of both endothelial cells and
pericytes. This has been well documented in the monocrotaline model of pulmonary hypertension (24). Using
this model, Stewart and colleagues (24) used fluorescent microbeads to document both breaks and abrupt
termination of precapillary vessels, a feature associated with severe pulmonary hypertension. The authors went
on to show how infusion of endothelial progenitor cells that synthesize endothelial nitric oxide synthase can
reverse the pulmonary hypertension in association with rebuilding the distal vasculature that had been
interrupted. In the clinical setting, a fulminant form of neoangiogenesis is associated with end-stage primary and
secondary forms of pulmonary hypertension (4). This does not produce an effective increase in pulmonary flow
through conduit channels, but rather represents structurally and functionally dysregulated vessels that resemble
tumor vessels (4). These abnormal angiogenic channels are thought to arise because of the proliferation of
“apoptosis-resistant” local endothelial cells or from the seeding of the lumen with circulating progenitor
endothelial cells (20).
A variety of pulmonary hypertension-inducing stimuli used in the experimental setting or related to clinical
disease are associated with histological evidence of loss of distal pulmonary arteries, assessed either by platelet
endothelial cell adhesion molecule (PECAM) staining of endothelial cells or by barium-gelatin infusion of the
lungs. Experimental stimuli in addition to chronic hypoxia that induce loss of vessels in association with
pulmonary hypertension have included injection of the toxin monocrotaline (23), monocrotaline and
pneumonectomy (17), exposure to chronic hyperoxia (11, 22), and creation of aortopulmonary shunts (19). In
the clinical setting, conditions associated with pulmonary hypertension and loss of arteries include congenital
heart defects (18), lung developmental abnormalities (2), and idiopathic pulmonary hypertension (16). Improved
resolution of current imaging techniques might, in the future, detect loss of precapillary arteries in association
with pulmonary hypertension in the clinical setting. Loss of arteries reflecting loss of vascular reserve might be
reflected in heightened pulmonary artery pressure and resistance with exercise or changes in pulmonary
vascular impedance, which most accurately represents the total right ventricular afterload, including both
steady and pulsatile right ventricular work requirements (21).
Unfortunately, only the minority of clinical or experimental studies of chronic hypoxia-induced pulmonary
hypertension report whether there is loss of precapillary vessels. One of the ways in which the number of
precapillary vessels is precisely determined is by barium-gelatin infusion. This barium permits radiographic
assessment of the circulation and the gelatin does not allow the contrast to pass into the capillary bed. Thus it is
easy to count barium-filled peripheral arteries at alveolar duct and wall level on microscopic examination of lung
tissue sections. Usually the number of precapillary arteries is recorded as the number of arteries relative to 100
alveoli or per squared millimeter. Calculating arteries per 100 alveoli makes the assumption that the alveoli are
normal in number and calculating squared millimeter makes the assumption that the number and size of alveoli
are normal.
In addition to distensibility analysis (21), microCT (8) can be used to support loss of filling of distal arteries
following exposure to chronic hypoxia using the barium-gelatin method or perfluorooctyl bromide (PFOB) as an
intravascular X-ray contrast agent. With this method, isolated lungs harvested from mice are rinsed of blood and
perfused with a physiological salt solution containing 5% bovine serum albumin while being ventilated with a
15% O2, 6% CO2, balance nitrogen mixture. Papavarine is added to the perfusate and recirculated prior to
imaging to remove residual muscle tone. The perfusate is then replaced with PFOB, which is trapped at the

precapillary level and only fills the arterial vasculature. High-resolution planar images are taken at an airway
pressure of 6 mmHg for a range of intravascular pressures (between 6 and 17 mmHg).
Alternatively, one can use vWF or PECAM staining of endothelium to landmark arteries accompanying alveolar
ducts and alveolar walls down to a precapillary size of 20 μm and to express those arteries relative to alveoli.
This technique runs the risk of including venules in the assessment, but venules can generally be differentiated
from arterioles since they are surrounded by loose connective tissue, they run in connective tissue septae in the
lung, and they often have prominent branches. One of our recent studies has shown excellent correlation
between the barium-gelatin and vWF immunostaining techniques to assess precapillary arteries (15). With these
techniques, a reduction in the number of arteries relative to alveoli has been documented in rodents with
chronic hypoxia-induced pulmonary hypertension in our laboratory (13, 14) and in that of others (3, 12).
Studies using transgenic mice have taught us that there can be tremendous discrepancies between the
hemodynamic assessments of pulmonary artery pressure and resistance and the remodeling response of the
distal circulation in terms of muscularization of distal vessels, hypertrophy of more proximal arteries, and loss of
arteries relative to alveoli. For example, in mice with overexpression of S100A4/Mts1, a baseline increase in
pulmonary artery pressure is further augmented by chronic hypoxia relative to controls, but we were unable to
identify an increase in the muscularization of distal vessels, in the loss of distal vessels landmarked as
precapillary, or in the wall thickness of normally muscular arteries that would explain this discrepancy. We did,
however, document marked changes in the elastin matrix (14, 15) that might have influenced the distensibility
characteristics in the pulmonary circulation (9, 10).
We observed that patchy deletion of BMPR1a in smooth muscle cells and others have reported that
haploinsufficiency of BMPRII results in equivalent pulmonary artery pressures found in wild-type mice exposed
to chronic hypoxia, but less structural remodeling of the distal circulation (1). New studies are considering the
contribution of the extracellular matrix, where an increase in aberrantly distributed elastin and collagen could
be associated with reduced compliance (9, 10) and thus increased impedance even when resistance is
unchanged.
So, the following might summarize what we believe is the basis for the difference of opinion regarding hypoxiamediated loss of distal arteries.
First, pulmonary hypertension is reversed with Rho kinase inhibitors. However, this does not negate the loss of
vessels, only that under basal conditions, the loss of distal arteries does not impair resting steady hemodynamics
of the pulmonary circulation.
Second, stereology shows increased angiogenesis and increased capillary length in hypoxia. This is well
documented but does not tell us about aberrant or “lost” connections between the precapillary and capillary
circulation.
Third, loss of arteries is not always seen in hypoxia. Certain methodologies like barium-gelatin injection are
designed to facilitate assessment of the distal precapillary pulmonary vasculature, but this method can be
technically challenging particularly in murine lungs. However, PECAM or vWF immunostaining validates the loss
of vessels when used in the same series of experiments and this should also be possible with microCT with PFOB.
Fourth, certain murine species may not show loss of arteries. This may be true despite the fact that other
features of remodeling of the pulmonary circulation are observed. Also, we need to look beyond the vascular
changes we have typically observed in chronic hypoxia-induced pulmonary hypertension into those that affect
the total right ventricular afterload, including both steady and pulsatile right ventricular work.
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